Scientific program

Thursday, October 11, 2018

 09:00 – 12:20 Pre-Congress Workshop 1:
From concept to publication: Clinical trials in cancer		 Hall B
Chairperson Arlene Chan, Australia
Speakers Arlene Chan, Australia – Medical oncology
Boon Chua, Australia – Radiation oncology
Andrew Spillane, Australia – Breast surgery
09:00 – 09:10 Opening: Goals and benefits of clinical research
Arlene Chan, Australia
09:10 – 09:40 Goals of workshop: Spectrum of research, GCP/NHMRC, trial conduct, protocol basics
Arlene Chan, Australia
  Questions from the audience
09:45 – 10:00 Phases of clinical trials, protocol development
Arlene Chan, Australia
  Regulatory, ethics and governance
Arlene Chan, Australia
10:00 – 10:30 Group activity
10:30 – 10:50 Coffee Break 
10:50 – 11:20 Group presentation and discussion
11:20 – 11:40 Scope and pitfalls of surgical research
Andrew Spillane, Australia
11:40 – 12:00 Scope and pitfalls of radiation oncology research
Boon Chua, Australia
12:00 – 12:15 How to present at a clinical meeting
Arlene Chan, Australia
12:15 – 12:20 Roundup
 09:00 – 12:20 Pre-Congress Workshop 2:
Pathology – shades of grey: When the answer is non-definitive		 Hall C
Chairperson Nirmala Pathmanathan, Australia
09:00 – 09:30 Spindle cell lesions of the breast and their significance
Stephen Fox, Australia
09:30 – 10:00 The spectrum of lesions from atypia to DCIS and lobular neoplasia, significance and management
Sunil Lakhani, Australia
10:00 – 10:30 Radial scars, papillomas and other benign proliferative lesions, significance and management
Gelareh Farshid, Australia
10:30 – 10:50 Coffee Break 
10:50 – 11:20 ER, PR and HER2 testing controversies and the classification of breast cancer
David Clouston, Australia
11:20 – 12:10 Breast cancer prognosis: Is grade still relevant?
Nirmala Pathmanathan, Australia
12:10 – 12:20 Panel discussion
 09:00 – 12:20 Pre-Congress Workshop 3:
The challenging patient		 Hall D
Chairperson Norman Swan, Australia
09:00 – 09:15 Who are the challenging patients and how do they challenge us?
Christobel Saunders, Australia
09:15 – 09:35 Can we understand their challenges?
Jane Turner, Australia
09:35 – 09:55 What are our legal obligations?
Ian Freckelton, Australia
09:55 – 10:15 The US experience
Reshma Jagsi, USA
10:15 – 10:30 Managing challenging patients clinician-patient encounters
Lesley Stafford, Australia
10:30 – 10:50 Coffee Break
10:50 – 12:20 Panel and audience discussion
Christobel Saunders, Australia, Ian Freckelton, Australia, Reshma Jagsi, USA, Lesley Stafford, Australia, Fran Boyle, Australia, Jane Turner, Australia, Alexis Butler, Australia, Kerry Shanahan, Australia, Danielle Spence, Australia
 12:20 – 13:20 Lunch break
 13:20 – 16:40 Pre-Congress Workshop 4:
Managing breast cancer in resource poor locations		 Hall B
Chairperson Jacinta Elston, Australia
13:20 – 13:30 Introduction
Jacinta Elston, Australia
13:30 – 14:00 East Timor – setting up a breast service in one of the world’s most resource poor nations
Alito Soares, Timor Leste
Danielle Spence, Australia
Christobel Saunders, Australia
14:00 – 14:20 Developing breast cancer services and advocacy in India
Raghu Ram, India
14:20 – 14:40 How to get radiotherapy to resource-poor nations
Mei Ling Yap, Australia
14:40 – 15:00 Coffee Break 
15:00 – 15:20 Breast cancer in Maori and Pasifika
Ian Campbell, New Zealand
15:20 – 15:50 Breast cancer in Indigenous Australia
Jacinta Elston, Australia
Jennifer Chynoweth, Australia
15:50 – 16:40 Panel discussion
Jacinta Elston, Australia; Alito Soares, Timor Leste; Danielle Spence, Australia; Christobel Saunders, Australia; Raghu Ram, India; Mei-Ling Yap, Australia; Ian Campbell, New Zealand; Jennifer Chynoweth, Australia; Josese Turageva, Fiji
 13:20 – 16:40 Pre-Congress Workshop 5:
Radiation oncology		 Hall C
Chairpersons Minjae Lah, Australia
Yvonne Zissiadis, Australia
13:20 – 13:25 Welcome and introduction of speakers
Minjae Lah, Australia
Yvonne Zissiadis, Australia
13:25 – 13:45 Post-mastectomy RT in node negative and N1 patients
Reshma Jagsi, USA
13:45 – 14:05 Discussion
14:05 – 14:25 Cardiotoxicity: When do we start to worry?
Lori Pierce, USA
14:25 – 14:50 Discussion
14:50 – 15:10 Coffee Break 
15:10 – 15:30 Integrating RT and breast reconstruction
Reshma Jagsi, USA
15:30 – 15:45 Discussion
15:45 – 16:00 Cardio-oncology programs: Part of our quality control?
Lori Pierce, USA
16:00 – 16:20 Q & A
 13:20 – 16:40 Pre-Congress Workshop 6:
The tortuous road to diagnosis		 Hall D
Chairperson Jill Evans, Australia
13:20 – 13:40 When is a lump a lump?
Jennifer O’Sullivan, Australia
13:40 – 14:10 Radiology:
Breastscreen assessment: Not always smooth sailing
Nick Repin, Australia
14:10 – 14:40 Imaging diagnostic conundrums
Liz Wylie, Australia
14:40 – 15:00 Coffee Break 
15:00 – 16:00 Surgery and Pathology:
Uncertainties and grey areas in breast pathology: When is surgical intervention needed?
Nirmala Pathmanathan, Australia
Elisabeth Elder, Australia
16:00 – 16:40 Panel and audience discussion
 17:15 – 17:30 Congress Opening Hall A
 17:30 – 19:00 Plenary Session 1:
Neoadjuvant therapy		 Hall A
Chairpersons Richard de Boer, Australia
Christobel Saunders, Australia
 17:30 – 18:00
17:30
17:40
17:50		 Debate: That decisions regarding NAST should be based on TN stage rather than breast cancer subtype
TN stage: Bruce Mann, Australia
Breast cancer subtypes: Stephen Johnston, UK
Discussion
 18:00 – 18:30 The potential of neoadjuvant endocrine therapy
Mitch Dowsett, UK
 18:30 – 19:00
18:30
18:40
18:50		 Debate: That further chemotherapy should be recommended for patients with ER-ve cancer not achieving pCR
Yes: Stacy Moulder, USA
No: Nicholas Wilcken, Australia
Discussion
 19:00 Networking Reception

Friday, October 12, 2018

07:00 – 08:30 Morning Industry Symposium: Practice-changing new perspectives on genomic profiling in the management of HR+, HER2- Early Breast Cancer
Supported by Genomic Health
Breakfast will be served prior to the session
 Hall A
07:00 – 08:30 Morning Industry Symposium: CDK4/6 inhibitors in advanced breast cancer: The future is now
Supported by Pfizer
Breakfast will be served prior to the session
 Hall B
 08:30 – 09:30 Parallel Session 2:
Screening		 Hall A
Chairpersons Gelareh Farshid, Australia
Allison Rose, Australia		  
 08:30 – 09:05
08:30
08:40
08:50		 Debate: That BreastScreen Australia requires urgent and radical reform
Yes: Alexandra Barratt, Australia
No: Bruce Mann, Australia
Discussion
 09:05 – 09:20 Mammographic density
Jack Cuzick, UK
09:20 – 09:30 Validation of iPrevent, an online breast cancer risk assessment and risk management decision support tool
Kelly-Anne Phillips, Australia
 08:30 – 09:30 Parallel Session 3:
Keeping patients on their endocrine treatments		 Hall B
Chairpersons Nicole McCarthy, Australia
Lisa Sheeran, Australia		  
08:30 – 08:50 The biology of endocrine side effects
Mitch Dowsett, UK
08:50 – 09:05 Below the breast: Managing genitourinary symptoms
Martha Hickey, Australia
 09:05 – 09:30
09:05
09:15
09:25		 Debate: How to best manage endocrine therapy symptoms: Pharma or sweat?
SWEAT: Prue Cormie, Australia
PHARMA: Fran Boyle, Australia
Discussion
 08:30 – 09:30 Parallel Session 4:
Free Papers: Medical oncology		 Hall C
Chairpersons Nick Murray, Australia
Catherine Oakman, Australia
08:30 – 08:40 Neoadjuvant chemotherapy rates for breast cancer in Australia: Are we there yet?
Paul Patiniott, Australia
08:40 – 08:50 Curative Intent Stereotactic Ablative Body Radiotherapy (SABR) in oligometastatic breast cancer:
Final results of a Phase I clinical trial
Steven David, Australia
08:50 – 09:00 Cryoablation of breast cancer in metastatic patients. Preliminary experience
Claudio Pusceddu, Italy
09:00 – 09:10 Ribociclib with endocrine therapy for premenopausal women with hormone receptor positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Additional results from the Monaleesa-7 trial
Louis Chow, Hong Kong
09:10 – 09:20 Canassist-breast: Unique immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia
S.P. Somashekhar, India
09:20 – 09:30 Phase 2 keynote-086 trial: Relationship between response to pembrolizumab and tumor infiltrating lymphocyte (TIL) levels in metastatic triple-negative breast cancer (mTNBC)
Sherene Loi, Australia
 09:30 – 11:00 Plenary Session 5:
Genetics		 Hall A
Chairpersons Geoff Lindeman, Australia
Lara Lipton, Australia		  
 09:30 – 10:00
09:30
09:40
09:50		 Debate: That most patients with breast cancer should be panel tested for germline mutations
Yes: Lucinda Salmon, Australia
No: Marion Harris, Australia
Discussion
10:00 – 10:30 The medical implications of panel testing: Platinums/PARPi’s
Rebecca Dent, Singapore
10:30 – 11:00
10:30
10:40
10:50		 Debate: That gene carriers diagnosed with cancer should be strongly advised to undergo bilateral  mastectomy
Yes: James French, Australia
No: Christopher Pyke, Australia
Discussion
 11:00 – 11:30 Coffee break and poster viewing
 11:30 – 12:30 Parallel Session 6:
Imaging		 Hall A
Chairpersons Seigo Nakamura, Japan
Belinda Yeo, Australia		  
 11:30 – 11:50 Assessment of response to neoadjuvant chemotherapy
Clair Shadbolt, Australia
11:50 – 12:10 New paradigms in breast imaging: The 7-8 minutes that make a difference
Allison Rose, Australia
 12:10 – 12:30 PET in breast cancer
Kate Moodie, Australia
11:30 – 12:30 Industry Symposium: Clinical controversies in HER2+ early breast cancer
Supported by Roche
 Hall B
 11:30 – 12:30 Parallel Session 7:
Free Papers: Surgery/Radiotherapy		 Hall C
Chairpersons Michael Chao, Australia
Sanjay Warrier, Australia
11:30 – 11:40 Radioactive iodine seed localization in axilla with sentinel node biopsy (RISAS): A Dutch prospective multicenter trial on axillary staging after neoadjuvant chemotherapy in node positive breast cancer
Natacha Ruyssers, Belgium
11:40 – 11:50 Spy fluoresence angiography: An adjunct to identifying cases suitable for staged breast reconstruction
Nita Bartlett, Australia
11:50 – 12:00 Intraoperative Assessment (IOA) of the Sentinel Node (SN) in breast cancer by One Step Nucleic acid Assay (OSNA): Warwick experience of over 1100 patients
Dayalan Clarke, UK
12:00 – 12:10 Implications of the St George randomized breast boost trial for reduced volume or dose breast radiotherapy strategies
Peter Graham, Australia
12:10 – 12:20 Active monitoring is an acceptable choice for women with low risk ductal carcinoma in situ (DCIS): An assessment of quality of life
Hannah Bromley, Australia
12:20 – 12:30 The UK-ANZ NeST (neoadjuvant systemic therapy in breast cancer) multicenter collaborative study
Stuart McIntosh, UK
 12:30 – 13:30 Lunch break and poster viewing
 13:30 – 14:30 Parallel Session 8:
Controversies in reconstruction		 Hall A
Chairpersons Elisabeth Elder, Australia
Andrew Spillane, Australia		  
 13:30 – 14:00
13:30
13:40
13:50		 Debate: That neoadjuvant RT prior to TM/reconstruction is a better approach than post-mastectomy RT
Yes: Caroline Baker, Australia
No: Boon Chua, Australia
Discussion
 
14:00 – 14:30
14:00
14:10
14:20		 Debate: That two-stage implant based reconstruction is rarely indicated in the setting of skin or nipple sparing mastectomy
Yes: James French, Australia
No: Dean Trotter, Australia
Discussion
13:30 – 14:30 Industry Symposium: New paradigms in the treatment of HR+HER2- mBC: CDK4/6 inhibitors and beyond
Supported by Novartis
 Hall B
 14:30 – 15:50 Plenary Session 9:
Adjuvant endocrine therapy		 Hall A
Chairperson Stephen Johnston, UK
Linda Vahdat, USA
14:30 – 14:40 What is the ER/PR threshold at which endocrine therapy should be prescribed, or may be relied upon?
Nirmala Pathmanathan, Australia
14:40 – 15:10
14:40
14:50
15:00		 Debate: That topical oestrogens are an acceptable treatment in pts with HR+ve early breast cancer
Yes: Yoland Antill, Australia
No: Catherine Oakman, Australia
Discussion
15:10 – 15:20 Update on SOFT/TEXT
Prue Francis, Australia
15:20 – 15:50
15:20
15:30
15:40		 Debate: That 10 years of AET is overtreatment
Yes: Janice Tsang, Hong Kong
No: Nicole McCarthy, Australia
Discussion
15:50 – 16:10 Coffee break and poster viewing
 16:10 – 17:30 Parallel Session 10:
Molecular assays		 Hall A
Chairpersons Bruce Mann, Australia
Louis Chow,Hong Kong		  
16:10 – 16:25 The case for using Oncotype DX
Virginia Kaklamani, USA
16:25 – 16:40 The case for using Endopredict
Mitch Dowsett, UK
16:40 – 16:55 The case for using Mammaprint
Alastair Thompson, USA
16:55 – 17:10 The case for using Prosigna
Janice Tsang, Hong Kong
17:10 – 17:25 The case for rarely using an assay
Belinda Yeo, Australia
17:25 – 17:30 Discussion
 16:10 – 17:30 Parallel Session 11:
Life after breast cancer		 Hall B
Chairperson Lesley Stafford, Australia
16:10 – 16:40 Risking another cancer: Who should have a mastectomy/CPM?
Laura Esserman, USA
16:40 – 17:00 Motivational interviewing: How to get the best lifestyle outcomes from your patients
Sarah Hardcastle, Australia
17:00 – 17:30 Brains (cognitive decline) and breast cancer
Adam Walker, Australia

Saturday, October 13, 2018

07:00 – 08:30 Morning Industry Symposium: Old favourites, new strategies: Chemotherapy and the treatment of MBC
Supported by Eisai
Breakfast will be served prior to the session
 Hall B
07:00 – 08:30 Morning Industry Symposium: Attractive techniques for localisation and staging: Tools for everyone
Supported by Magseed
Breakfast will be served prior to the session
 Hall C
 08:30 – 09:30 Parallel Session 12:
DCIS		 Hall A
Chairpersons Christopher Pyke, Australia
Yvonne Zissiadis, Australia		  
 08:30 – 09:00
08:30
08:40
08:50		 Debate: That RT after WE for DCIS is usually overtreatment
Yes: Laura Esserman, USA
No: Lori Pierce, USA
Discussion
 09:00 – 09:20 Active surveillance is an option for low-risk DCIS
Christobel Saunders, Australia
09:20 – 09:30 Discussion
 08:30 – 09:30 Parallel Session 13:
Topics in chemotherapy		 Hall B
Chairpersons Rebecca Dent, Singapore
Elgene Lim, Australia		  
 08:30 – 09:00
08:30
08:40
08:50		 Debate: That dose-dense chemotherapy should be the standard for all subtypes of early breast cancer
Yes: Linda Vahdat, USA
No: Richard de Boer, Australia
Discussion
09:00 – 09:15 New strategies in early stage TNBC
Stacy Moulder, USA
09:15 – 09:30 Will NGS become a standard part of management of breast cancer?
Sarah-Jane Dawson, Australia
 08:30 – 09:30 Parallel Session 14:
Free Papers: Screening/Treatment effects/Supportive care		 Hall C
Chairpersons Jocelyn Lippey, Australia
Kerry Shanahan, Australia
08:30 – 08:40 Liposuction for advanced breast cancer-related lymphoedema: Outcomes of a multidisciplinary team approach
John Boyages, Australia
08:40 – 08:50 Identification of breast cancer survivors’ side effects and supportive care needs
Christina Kozul, Australia
08:50 – 09:00 Physical function following breast reconstructive surgery: Are musculoskeletal side-effects a problem?
Deirdre McGhee, Australia
09:00 – 09:10 Patient reported experiences from the persephone early breast cancer trial
Janet Dunn, UK
09:10 – 09:20 Prospective three-arm triple-blinded comparative study for breast cancer screening in low resource setting countries with a noninvasive and low-cost technique using a handheld point-of-care medical device (iBreastexam)
S.P. Somashekhar, India
09:20 – 09:30 Health system barriers to the provision of breast reconstruction options in Australia: Improving informed choice through appropriate referral
Kathy Flitcroft, Australia
 09:30 – 11:00 Plenary Session 15:
Loco-Regional therapy		 Hall A
Chairpersons Caroline Baker, Australia
Boon Chua,Australia
 09:30 – 10:00
09:30
09:40
09:50		 Debate: That all patients with axillary nodal disease pre-NACT should have axillary dissection or radiation
Yes: Yvonne Zissiadis, Australia
No: Jane O’Brien, Australia
Discussion
 10:00 – 10:20 The implications of the AMAROS study
Lori Pierce, USA
10:20 – 11:00
10:20
10:35
10:50		 Debate: That regional nodal radiation is appropriate for most patients with nodal disease
Yes: Reshma Jagsi, USA
No: Louis Chow, Hong Kong
Discussion
11:00 – 11:30 Coffee break and poster viewing
 11:30 – 13:00 Parallel Session 16:
Local therapy		 Hall A
Chairpersons James French, Australia
Jane Fox, Australia
 11:30 – 12:00
11:30
11:40
11:50		 Debate: Margins: That “no tumour on ink” is a dangerous over-simplification
Yes: Ian Campbell, New Zealand
No: S.P. Somashekhar, India
Discussion
 12:00 – 12:30 The status of intra-operative techniques for localization/margin assessment
Alistair Thompson, USA
12:30 – 13:00
12:30
12:40
12:50		 Debate: That IORT is ready for prime time
Yes: Dennis R. Holmes, USA
No: Michael Chao, Australia
Discussion
11:30 – 13:00 Industry Symposium: Key issues around bone health
Supported by Amgen
 Hall B
10:30 – 13:00 Breast Cancer Network Australia: Metastatic breast cancer
 Hall C
13:00 – 14:00 Lunch break and poster viewing
 14:00 – 15:00 Parallel Session 17:
Exercise and lymphoedema		 Hall A
Chairpersons Kerry Shanahan, Australia
Lisa Sheeran, Australia
14:00 – 14:20 Surgery for lymphoedema: A new paradigm
Ramin Shayan, Australia
14:20 – 14:40 Prescribing exercise and putting it into practice
Prue Cormie, Australia
14:40 – 15:00 Wearable technology and influencing health behaviours
Sarah Hardcastle, Australia
 14:00 – 15:00 Parallel Session 18:
CNS metastases		 Hall B
Chairpersons Minjae Lah, Australia
Stacy Moulder, USA
  
14:00 – 14:20 Molecular pathology of CNS metastases
Sunil R. Lakhani, Australia
14:20 – 14:40 Local therapy for CNS metastases: The roles of surgery, SRS and WBRT in 2018
Claire Phillips, Australia
14:40 – 15:00 Drug treatment for CNS metastasis
Arlene Chan, Australia
 14:00 – 15:00 Parallel Session 19:
Breast surgery		 Hall c
Chairpersons Ian Campbell, New Zealand
S.P. Somashekhar, India
14:00 – 14:15 Onco-anaesthesia: Is anaesthetic technique a risk factor for outcome?
Bernhard Riedel, Australia
 14:15 – 14:45
14:15
14:25
14:35		 Debate: That percutaneous ablation is a useful treatment option in early breast cancer
Yes: Dennis Holmes, USA
No: Andrew Spillane, Australia
Discussion
 14:45 – 15:00 How should quality of life be assessed after breast cancer surgery
Elisabeth Elder, Australia
 15:00 – 16:15 Plenary Session 20:
Breast Cancer 2025		 Hall A
Chairpersons Christobel Saunders, Australia
Yvonne Zissiadis, Australia		  
15:00 – 15:15 Breast cancer prevention in 2025
Jack Cuzick, UK
15:15 – 15:30 A pathologist’s view of breast cancer in 2025
Sunil R. Lakhani, Australia
15:30 – 15:45 How might immunotherapy be used in breast cancer?
Sherene Loi, Australia
15:45 – 16:00 A radiation oncologist’s view of breast cancer in 2025
Reshma Jagsi, USA
16:00 – 16:15 A surgeon’s view of breast cancer in 2025
Laura Esserman, USA
16:15 – 16:30 Congress closing and Award presentation
 Hall A
Chairpersons Christobel Saunders, Australia
Yvonne Zissiadis, Australia
Bruce Mann, Australia